WisdomTree, 21Shares to list crypto products on London Stock Exchange

WisdomTree, 21Shares to list crypto products on London Stock Exchange

Technology

WisdomTree, 21Shares to list crypto products on London Stock Exchange

Follow on
Follow us on Google News
 

LONDON (Reuters) - WisdomTree (WT.N), opens new tab and 21Shares are to launch exchange-traded products (ETPs) backed by cryptocurrencies on the London Stock Exchange, the firms said on Wednesday after getting the green light from Britain's financial regulator.

The planned listings, set to be the first in the UK, come after Britain's Financial Conduct Authority (FCA) in March approved the launch of what it called "cETNs" - cryptoasset-backed exchange traded notes - for professional investors.

Investors are increasingly buying cryptocurrencies via ETPs, even as regulators warn about the risks.

Bitcoin's price surged after the US Securities and Exchange Commission (SEC) approved bitcoin exchange-traded funds in January, and cryptocurrencies have gained in recent days on expectations that the SEC will approve a similar product for the second-biggest cryptocurrency, ether .

The two WisdomTree products give investors exposure to the underlying cryptocurrencies: one for bitcoin and one for ether.

They are expected to be listed on May 28, asset manager WisdomTree said in a statement, adding that it was "amongst the first issuers" to have its crypto ETPs approved by the FCA.

"While UK-based professional investors have been able to allocate to crypto ETPs via overseas exchanges, they will soon have a more convenient access point," said Alexis Marinof, WisdomTree's head of Europe.

"FCA approval in this respect could result in greater institutional adoption of the asset class."

"London hosts one of the deepest, most liquid capital markets in the world - where there is proven institutional interest in cryptocurrencies," it said in a statement.

The FCA has stated that cryptocurrencies are highly risky and largely unregulated.

It bans selling them to retail investors, saying the products are "ill-suited for retail consumers due to the harm they pose".